# Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

- Source: PR Newswire M&A
- Published: 2026-11-05T11:45:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lilly-to-showcase-new-retatrutide-taltz-ixekizumab-and-zepbound-tirzepatide-data-at-acr-convergence-2026-advancing-science-at-the-intersection-of-rheumatologic-conditions-and-obesity-302930037.html
- Canonical: https://groundlevelnews.com/story/lilly-to-showcase-new-retatrutide-taltz-ixekizumab-and-zepbound-tirzep-c45d71/

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._